ArticleFrontiers in oncology2026
Arginine is a protective factor for risk and prognosis of gastric cancer: an observational and Mendelian randomization study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous research has indicated that certain amino acids possess anti-tumor properties. However, the impact of blood amino acid levels on the risk of gastric cancer remains uncertain, and a comprehensive analysis examining the association between blood amino acids and the prognosis of gastric cancer is lacking. Methods: We performed a Mendelian randomization analysis to explore the link between 22 blood amino acids and gastric cancer risk. We also assessed how these amino acids affect gastric cancer prognosis using Cox regression analyses and visualized this with Kaplan-Meier survival curves. A nomogram prognostic model was developed, and its predictive value was evaluated using ROC curves. Additionally, we examined the effects of a key amino acid on cell proliferation and gene expression in gastric cancer cells through CCK-8 assays and transcriptomic sequencing, followed by GO and KEGG pathway analyses to understand the molecular regulation of responsive genes. Results: Our study revealed a significant negative correlation between arginine levels and the risk of gastric cancer. Moreover, only arginine emerged as an independent prognostic factor for gastric cancer, regardless of age, sex, stage, differentiation, and other amino acids. Furthermore, the nomogram prognostic model, incorporating arginine, sex, age, differentiation, and stage, demonstrated a robust prognostic ability. The area under the curve (AUC) for predicting 1-year, and 3-year survival rates were 0.949 and 0.962, respectively. The CCK-8 analysis showed that higher arginine levels inhibited gastric cancer cell growth. Additionally, GO and KEGG enrichment profiling revealed that the identified DEGs were primarily involved in metabolism pathway and protein-binding function. Conclusion: Arginine is a protective factor for the risk and prognosis of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.